Table 1 Baseline characteristics of patients receiving anakinra for gouty arthritis.
From: Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases
Baseline characteristics | Clinical characteristics of gouty patients |
|---|---|
Number of patients | 40 |
Number of men (%) | 32 (80%) |
Comorbid conditions (number; %) | HT (27; 68%), CKD 3-5 (22; 55%), CAD (17; 43%), AI (13; 33%), DM (9; 23%), GU (6; 15%), transplant (2 (kidney, heart); 5%), asthma (1; 3%), |
Associated therapies (number; %) | LDA (8; 20%), oral anticoagulant (3; 8%), |
Age, year, mean ± SD | 60.0 ± 13.9 |
Disease duration, year, mean ± SD | 8.7 ± 8.7 |
Flare duration, number patients (days, mean ± SD) | |
Acute (<6 weeks) | 34 (9.4 ± 8.1) |
Subacute (6 to12 weeks) | 2 (60.0 ± 1.4) |
Chronic (>12 weeks) | 4 (130 ± 45.8) |
Localization of arthritis, (number; %) | Knees (30; 75%), wrists (22; 55%), ankles (24; 60%), MTP1s (20; 50%), MCPs (12; 30%), elbows (12; 30%), tarsae (6; 15%), shoulders (2; 5%) |
Reason for anakinra use | |
Non-response to conventional therapies, (number; %) | Colchicine (24; 60%), NSAIDs (11; 27.5%), steroids (7; 17.5%) |
Adverse events or contraindication to conventional therapies, (number; %) | Colchicine (16; 40%), NSAIDs (29; 72.5%), steroids (9; 22.5%) |